Inmune Bio (INMB) Common Equity (2017 - 2026)
Inmune Bio (INMB) posted Common Equity of $20.36 million for Q2 2026, down 29.5% from $28.87 million a year earlier but up 3.8% from the prior quarter.
Powered by 
Analysis
Inmune Bio (INMB) Common Equity (2017 - 2026) Analysis & Trends
At the end of FY2025, Inmune Bio's Common Equity came in at $23.52 million, down 26.7% from FY2024.
- Annual Common Equity has declined for four consecutive years, with a five-year compound annual growth rate of -9.5% (FY2020 to FY2025).
- In prior years, Inmune Bio's Common Equity was $32.1 million in FY2024 (-14.0%), $37.34 million in FY2023 (-37.9%), $60.1 million in FY2022 (-25.1%) and $80.23 million in FY2021 (+107.0%).
- Quarterly Common Equity has run from a low of $19.62 million in Q1 2026 to a high of $88.26 million in Q3 2021 over five years.
- On a year-over-year basis, Common Equity has declined in each of the last five quarters, with an average decline of 20.7% over the last eight quarters.
- The strongest year-over-year quarter for Common Equity in the past five years was Q3 2021, with growth of 114.2%; the weakest was Q1 2024, with a decline of 49.0%.
- According to Business Quant data, Common Equity for the three prior quarters was $19.62 million (Q1 2026), $23.52 million (Q4 2025) and $25.38 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Inmune Bio | 55.31 Mn | -36.95 Mn | - | 20.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.36 Mn |
| Mar 31, 2026 | 19.62 Mn |
| Dec 31, 2025 | 23.52 Mn |
| Sep 30, 2025 | 25.38 Mn |
| Jun 30, 2025 | 28.87 Mn |
| Mar 31, 2025 | 29.67 Mn |
| Dec 31, 2024 | 32.10 Mn |
| Sep 30, 2024 | 38.68 Mn |
| Jun 30, 2024 | 36.28 Mn |
| Mar 31, 2024 | 28.22 Mn |
| Dec 31, 2023 | 37.34 Mn |
| Sep 30, 2023 | 43.93 Mn |
| Jun 30, 2023 | 50.65 Mn |
| Mar 31, 2023 | 55.30 Mn |
| Dec 31, 2022 | 60.10 Mn |
| Sep 30, 2022 | 63.71 Mn |
| Jun 30, 2022 | 69.93 Mn |
| Mar 31, 2022 | 75.64 Mn |
| Dec 31, 2021 | 80.23 Mn |
| Sep 30, 2021 | 88.26 Mn |
API Access
Inmune Bio Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=INMB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "INMB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=INMB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();